Implementation of a new specific program for training curators at Hiroshima University

博物館法施行規則の改正に伴い，2012年4月から学芸員資格取得のために修得すべき科目が大幅に変更となった。学芸員資格取得の歴史においてはきわめて大きな変更である。本学では，これに対応するため，各学部の学芸員資格取得特定プログラムを統合し，全学の学生を対象とする新課程に移行した。本稿では，本学が新たに採用した4学期制（ターム制）を含め，今回の変更が受講や資格取得にどのような影響を及ぼしたのか，統計データの分析を通じて考察した。新課程移行の前後で，プログラム登録者数，資格取得者数は大幅に減少し，取得率も大きく低下した。こうした現象は特定の学部，分野の変化に基づくものではなく，旧課程においてプログラム登録の主体となってきた全ての学部に共通する。分析を通じて，大幅な必要単位数の増加，全学を対象としたプログラムへの変更，2学期制から4学期制（ターム制）への変更など，複数の要因が関連して，各学部における専門の修得と学芸員資格取得を両立させることが困難な状況が生じていることが推定された。As a result of the revision of Museum Law Enforcement Rules, the subjects that must be completed to acquire the curator qualification have changed significantly since April 2012, which constitutes a major change in the history of this qualification. To cope with this change, we integrated the curator qualification specific programs of each faculty into a new course for students of all universities. In this paper, through statistical data analysis, we examined the impact of this change on attendance trends, including the term system newly adopted by Hiroshima University. Before and after the transition to the new course, the number of program registrants and qualifications greatly decreased, and the acquisition rate has also declined significantly. These phenomena were not based on changes in specific faculties or fields, but are common to all faculties subject to program registration during the old course. Through this analysis, we presumed that several factors, such as the great increase in the required number of credits, the change to the program for the whole school, and the change from a two-semester system to the four-semester system, were all interrelated to each other, which make it difficult to achieve both specialized and curator qualifications.本稿は，2018年6月22日に香川大学で開催された第13回日本博物科学会で口頭発表した藤野次史・青木孝夫・清水則雄・菅村 亨・本多博之・山口富美夫・山崎博史・吉田将之「広島大学における新課程実施後の学芸員資格取得状況について」を元に，新たなデータを加えて考察したものである

A novel high-throughput (HTP) cloning strategy for site-directed designed chimeragenesis and mutation using the Gateway cloning system

There is an increasing demand for easy, high-throughput (HTP) methods for protein engineering to support advances in the development of structural biology, bioinformatics and drug design. Here, we describe an N- and C-terminal cloning method utilizing Gateway cloning technology that we have adopted for chimeric and mutant genes production as well as domain shuffling. This method involves only three steps: PCR, in vitro recombination and transformation. All three processes consist of simple handling, mixing and incubation steps. We have characterized this novel HTP method on 96 targets with >90% success. Here, we also discuss an N- and C-terminal cloning method for domain shuffling and a combination of mutation and chimeragenesis with two types of plasmid vectors

Subsurface velocity structure and site amplification characteristics in Mashiki Town, Kumamoto Prefecture, Japan, inferred from microtremor and aftershock recordings of the 2016 Kumamoto earthquakes

In order to investigate the seismic velocity structure in the region of concentrated severe damage during the 2016 Kumamoto earthquake sequence, we conducted continuous seismic observations in the central area of Mashiki Town, Kumamoto Prefecture. During 4 days of observations at eight temporary sites, 2 months after the mainshock, recordings from 30 aftershocks (1.7 ≤ Mj ≤ 4.3, 1.9 km ≤ depth ≤ 13.5 km) were obtained. The aftershock data showed that site amplifications at approximately 1 Hz are dominant in a zone where almost no buildings were damaged along the Akitsu riverside, whereas site amplifications at higher than 3 Hz are observed in the heavily damaged zones. Our data also showed that the peak acceleration and velocity amplitudes, as well as seismic intensities for the small events in the less damaged zone, are clearly larger than those in the damaged zones, implying that the damage distribution is inconsistent with site response based on linear site amplifications. The estimated phase velocities of Rayleigh waves using the aftershock and microtremor data show dispersive characteristics in the lower frequency range (0.26 ≤ f ≤ 1.27 Hz), but the values are substantially smaller than those derived from the P–S logging model at the nearest KiK-net strong-motion observation station KMMH16. The derived microtremor horizontal-to-vertical spectral ratios and earthquake radial-to-vertical (R/V) spectral ratios show common distinct peaks at around 0.4 Hz, which are possibly related to the response of deep sedimentary layers beneath the area. The refined velocity structure model that better accounts for both the phase velocity and common dominant peak indicates that the values of S wave velocity (Vs) above the bedrock layer (Vs = 2700 m/s) are smaller than those inferred from the logging model and the depth to the bedrock layer could be much deeper (about 600 m) in comparison with the logging model (234 m). The derived R/V spectral ratio at station KMMH16 also shows a distinct peak at 0.4 Hz, suggesting that there is no large difference of deep sedimentary structure between the observation area and station KMMH16

ヒドロコルチゾン投与は日本人心肺停止患者の生存率改善に関連する

There are few reports on hydrocortisone administration after cardiac arrest, and those that have been published included few subjects. This study aimed to evaluate the effect of hydrocortisone administration on the outcomes of patients who experienced cardiac arrest. We investigated the survival discharge rates and the length of hospital stay from cardiac arrest to discharge, stratified by use of hydrocortisone, using a Japanese health-insurance claims dataset that covers approximately 2% of the Japanese population. The study included the data of 2233 subjects who experienced either in-hospital or out-of-hospital cardiac arrest between January 2005 and May 2014. These patients were divided into two groups, based on the administration of hydrocortisone. We adjusted the baseline characteristics, medical treatment, and drug administration data of the two groups using propensity scores obtained via the inverse probability of treatment weighted method. The hydrocortisone group had a significantly higher survival discharge rate (13/61 [21.1%] vs. 240/2172 [11.0%], adjusted odds ratio: 4.2, 95% CI: 1.60–10.98, p = 0.004). In addition, the administration of hydrocortisone was independent predictor of survival to discharge (hazard ratio: 4.6, p < 0.001). The results demonstrate a correlation between hydrocortisone administration and the high rates of survival to discharge

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).

INTRODUCTION: Since the SARS-CoV-2 Omicron variant became dominant, assessing COVID-19 vaccine effectiveness (VE) against severe disease using hospitalization as an outcome became more challenging due to incidental infections via admission screening and variable admission criteria, resulting in a wide range of estimates. To address this, the World Health Organization (WHO) guidance recommends the use of outcomes that are more specific to severe pneumonia such as oxygen use and mechanical ventilation. METHODS: A case-control study was conducted in 24 hospitals in Japan for the Delta-dominant period (August-November 2021; "Delta") and early Omicron (BA.1/BA.2)-dominant period (January-June 2022; "Omicron"). Detailed chart review/interviews were conducted in January-May 2023. VE was measured using various outcomes including disease requiring oxygen therapy, disease requiring invasive mechanical ventilation (IMV), death, outcome restricting to "true" severe COVID-19 (where oxygen requirement is due to COVID-19 rather than another condition(s)), and progression from oxygen use to IMV or death among COVID-19 patients. RESULTS: The analysis included 2125 individuals with respiratory failure (1608 cases [75.7%]; 99.2% of vaccinees received mRNA vaccines). During Delta, 2 doses provided high protection for up to 6 months (oxygen requirement: 95.2% [95% CI:88.7-98.0%] [restricted to "true" severe COVID-19: 95.5% {89.3-98.1%}]; IMV: 99.6% [97.3-99.9%]; fatal: 98.6% [92.3-99.7%]). During Omicron, 3 doses provided high protection for up to 6 months (oxygen requirement: 85.5% [68.8-93.3%] ["true" severe COVID-19: 88.1% {73.6-94.7%}]; IMV: 97.9% [85.9-99.7%]; fatal: 99.6% [95.2-99.97]). There was a trend towards higher VE for more severe and specific outcomes. CONCLUSION: Multiple outcomes pointed towards high protection of 2 doses during Delta and 3 doses during Omicron. These results demonstrate the importance of using severe and specific outcomes to accurately measure VE against severe COVID-19, as recommended in WHO guidance in settings of intense transmission as seen during Omicron